We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

231 hedge funds and large institutions have $2.61B invested in Axsome Therapeutics in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 90 increasing their positions, 54 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 16

75% more call options, than puts

Call options by funds: $106M | Put options by funds: $60.5M

67% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 54

33% more capital invested

Capital invested by funds: $1.97B → $2.61B (+$647M)

17% more funds holding

Funds holding: 197 → 231 (+34)

4.83% more ownership

Funds ownership: 73.31% → 78.14% (+4.8%)

11% less funds holding in top 10

Funds holding in top 10: 9 → 8 (-1)

Holders
231
Holders Change
+34
Holders Change %
+17.26%
% of All Funds
3.63%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
50
Increased
90
Reduced
54
Closed
16
Calls
$106M
Puts
$60.5M
Net Calls
+$45.1M
Net Calls Change
+$22.7M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$73.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$56.4M
3
RI
RTW Investments
New York
+$37.1M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$34M
5
DTC
Deep Track Capital
Connecticut
+$28.3M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$51.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$44.7M
3
Holocene Advisors
Holocene Advisors
New York
-$32.6M
4
Millennium Management
Millennium Management
New York
-$22.4M
5
WP
Woodline Partners
California
-$9.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
GTC
51
Ghost Tree Capital
New York
$7.9M -$8.48M -115,000 -51%
PCM
52
Peregrine Capital Management
Minnesota
$7.73M -$55.2K -748 -0.7%
Allspring Global Investments
53
Allspring Global Investments
North Carolina
$7.37M +$7.45M +101,027 +6,370%
N
54
Nuveen
North Carolina
$7.27M -$982K -13,307 -12%
HA
55
HHLR Advisors
Cayman Islands
$7.19M +$7.38M +100,000 New
WCM Investment Management
56
WCM Investment Management
California
$6.77M +$423K +5,733 +6%
MB
57
MPM BioImpact
Massachusetts
$6.73M +$1.71M +23,184 +33%
AGP
58
Artia Global Partners
Florida
$6.31M +$6.48M +87,848 New
Walleye Capital
59
Walleye Capital
New York
$6.2M +$6.36M +86,280 New
LC
60
Lindbrook Capital
California
$6.07M +$18.3K +248 +0.3%
WP
61
WMS Partners
Maryland
$5.75M -$8.36M -113,289 -59%
HWAM
62
Hennion & Walsh Asset Management
New Jersey
$5.57M -$1.24M -16,827 -18%
Swiss National Bank
63
Swiss National Bank
Switzerland
$5.45M +$406K +5,500 +8%
SSA
64
Schonfeld Strategic Advisors
New York
$5.41M +$4.79M +64,999 +630%
MIM
65
Monashee Investment Management
Massachusetts
$5.39M +$5.53M +75,000 New
PFM
66
Privium Fund Management
Netherlands
$5.27M -$6.45M -87,442 -55%
National Bank of Canada
67
National Bank of Canada
Quebec, Canada
$4.99M +$5.12M +69,423 New
MAP
68
Moody Aldrich Partners
Massachusetts
$4.65M +$2.37M +32,114 +99%
Citigroup
69
Citigroup
New York
$4.51M +$1.06M +14,436 +30%
CS
70
Credit Suisse
Switzerland
$4.35M +$1.5M +20,350 +51%
IBT
71
International Biotechnology Trust
United Kingdom
$4.19M +$4.3M +58,300 New
Deutsche Bank
72
Deutsche Bank
Germany
$4.14M -$533K -7,220 -11%
VOYA Investment Management
73
VOYA Investment Management
Georgia
$3.99M +$3.19M +43,294 +356%
CS
74
Candriam SCA
Luxembourg
$3.6M -$3.32M -45,000 -47%
HS
75
HighVista Strategies
Massachusetts
$3.55M -$839K -11,374 -19%
1 2
3
4 5

AXSM Hedge Fund Activity: Q2 2023 in Review

231 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2023, worth a combined $2.61B — up 33% from $1.97B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new AXSM positions and 16 closed out — a net gain of 34 holders — while 90 added to existing stakes and 54 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $73.8M. The largest seller was Point72 Asset Management, cutting an estimated $51.8M.

  • 231 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2023, up from 197 in Q1 2023.
  • Funds reported $2.61B of Axsome Therapeutics stock for Q2 2023, up 33% quarter-over-quarter.
  • 50 funds opened new Axsome Therapeutics positions in Q2 2023 and 16 closed out, a net change of +34 holders.
  • The largest Axsome Therapeutics buyer in Q2 2023 was RA Capital Management, an estimated $73.8M added.
  • The largest Axsome Therapeutics seller in Q2 2023 was Point72 Asset Management, an estimated $51.8M sold.

Based on aggregated 13F filings for Q2 2023.